Nevertheless, inconsistency in Ki-67 assessment in moderately differentiated breast cancer is widely observed and the use of Ki-67 biomarker is controversially discussed as a parameter for treatment decisions in such breast cancer patients. Here, MKI67 is linked to breast cancer.